Agile Therapeutics, Inc. (NASDAQ:AGRX) Stock Traded 15.2% Above Its 50 Day Moving Average


Company shares are trading at $5.00 which is significantly higher than $4.34, the 50 day moving average and which is significantly above the 200 day moving average of $3.83. The 50 day moving average went up $0.66 or +15.18% and the 200 day average was up $1.17. Agile Therapeutics, Inc. shares had a trading volume of 208K in the last trading session. Volume was up 210.42% over the stocks average daily volume.

Investors are feeling more bullish on Agile Therapeutics, Inc. recently as shown by the downtick in short interest. The stock experienced a fall in short interest of -1.30% as of the latest report on September 29, 2017. Short shares fell 6,202 over that period. Days to cover decreased 0.0 to 2.0 and the percentage of shorted shares is 0.02% as of September 29.

Additionally, here are a few investment firms who have increased or decreased their stake in (AGRX). Kcg Holdings, Inc. expanded its stake by buying 1,714 shares an increase of 15.3% from 03/31/2017 to 06/30/2017. Kcg Holdings, Inc. currently owns 12,924 shares worth $48,000. The value of the position overall is up by 33.3%. Pura Vida Investments, LLC grew its investment by buying 10,000 shares an increase of 6.1% in the quarter. Pura Vida Investments, LLC controls 174,501 shares valued at $654,000. The total value of its holdings increased 24.1%.

As of the end of the quarter Ubs Group Ag had acquired 1,946 shares growing its position 648.7%. The value of the investment in Agile Therapeutics, Inc. went from $1,000 to $8,000 a change of $7,000 since the last quarter. As of quarter end Meeder Asset Management Inc had bought a total of 1,468 shares growing its stake by 811.0%. The value of the investment in (AGRX) increased from $1,000 to $7,000 a change of 600.0% quarter over quarter.

Equity analyst H.C. Wainwright starting coverage on AGRX setting a rating of “Buy”. On October 2 analysts at H.C. Wainwright began coverage of AGRX with an initial rating of “Buy” and setting a price target of $10.00.

In the latest earnings report the EPS was $-0.97 and is expected to be $-1.02 for the current year with 28,806,000 shares currently outstanding. Next quarter’s EPS is forecasted to be $-0.26 and the next full year EPS is projected to be $-0.98.

Agile Therapeutics, Inc., launched on December 5, 1997, is a women’s health specialty pharmaceutical company. The Company is focused on the development and commercialization of prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options. The Company has developed a transdermal patch technology, called Skinfusion. The Business’s lead product candidate is Twirla, also known as AG200-15. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period..